Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of AK2017 injection for idiopathic short stature
CTR20253610Phase 3Active
- Sponsor
- Anke Bio
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of AK2017 in Idiopathic Short Stature (ISS), sponsored by Anke Bio. Started Dec 2025; status: active.
02
Drugs
AK2017
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on CTR20253610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253610.